Kornimate/medical-research-clean huggingface dataset:
chronic hand eczema - self-management and prognosis

Conditions: Chronic Hand Eczema; Chronic Hand Dermatitis

Summary: hand eczema is a common disease which often gives a chronic course thus affecting many functions in daily life. the body of evidence related to self-management of chronic hand eczema is poor. better methods to support self-management of patients with chronic hand eczema may potentially improve the prognosis of a disease which is both a tremendous burden to the individual and to the society. the purpose of this trial is to evaluate the effect of a newly designed guidance programme offering individual counselling compared to conventional information with written information sheets.

detailed description of the trial and the intervention can be found in the publication: mollerup a, veien nk, johansen jd. chronic hand eczema--self-management and prognosis: a study protocol for a randomised clinical trial'. bmc dermatol. 2012 jun 12;12:6. doi: 10.1186/1471-5945-12-6. pmid: 22691871 \[pubmed - indexed for medline\] free pmc article

Eligibility criteria:
inclusion criteria: * patients clinically diagnosed with hand eczema at the first medical consultation at the outpatient ward, copenhagen university hospital gentofte or at a private dermatologic practise in aalborg, denmark * patients who have given a signed informed consent to participate exclusion criteria: * patients who cannot reply to a questionnaire in danish

Keywords: hand eczema hand dermatitis chronic hand eczema chronic hand dermatitis contact dermatitis skin disease self-management
degarelix in the treatment of endometriosis recurrence

Conditions: Endometriosis

Summary: the long acting gnrh antagonist degarelix will be tested for the treatment of women with endometriosis recurrence compared with classical gnrh analog treatment. pain symptom disappearance and disease free time during follow-up will be the outcomes for establishing which medical treatment is the best in endometriosis recurrence treatment.

endometriosis is a chronic disease affecting 5-10% of women in reproductive age, showing recurrence after surgery at least in 20-50% after 5 years of follow-up. the long acting gnrh antagonist degarelix, which do not have the flare-up effect at the opposite of gnrh agonist and strongly suppress lh secretion and thecal cell activity may show a better effects on endometrial implants than gnrh agonist.

Eligibility criteria:
inclusion criteria: * women affected by endometriosis showing recurrence of pain symptoms * previous surgery for endometriosis exclusion criteria: * presence of other systemic diseases

Keywords: endometriosis long acting gnrh antagonist degarelix recurrence pelvic pain
drug-coating balloon treatment in coronary artery disease

Conditions: Coronary Artery Disease

Summary: drug-coated balloon (dcb) is an alternative choice for patients with coronary artery disease (cad). this study is to investigate the efficacy and safety of dcb treatment in patients with cad.

this is a prospective, multi-center, registry to enroll patients undergoing dcb treatment. all subjects undergoing dcb treatment will be enrolled in this study without strict inclusion and exclusion criteria. data and images will be collected during the index procedure, and at the clinical and angiographic follow-up.

Eligibility criteria:
inclusion criteria: * patients suitable for dcb treatment exclusion criteria: * pregnancy * contraindications to contrast media, antiplatelet therapy, or paclitaxel * expected life less than 12 months * cardiac shock
vyvanse and glucose intolerance in children with attention deficit hyperactivity disorder (adhd) and obesity

Conditions: Attention Deficit Hyperactivity Disorder; Glucose Intolerance; Obesity

Summary: the purpose of this study to assess the effects of chronic administration of vyvanse (lis-dexamphetamine) on glucose metabolism in a sample of children and adolescents with attention deficit hyperactivity disorder (adhd) who also have glucose intolerance and are obese.


Eligibility criteria:
inclusion criteria: * male or female, ages between 8 and 17 * body mass index \> 30 * fasting blood sugar between 90-100 mg/dl * 2 hour post prandial \>140 \<180 mg/dl * meets criteria for a diagnosis of adhd, any subtype exclusion criteria: * known cardiovascular disease or diabetes * structural cardiac abnormalities, abnormal ecgs, family history of sudden death * positive urine drug screen * fasting blood sugar level \> 126 mg/dl * hba1c \> 6.5 % * weight \> 300 lbs

Keywords: adhd glucose intolerance obesity vyvanse
evaluation of different methods to measure muscle mass and strength in a population with class ii/iii obesity

Conditions: Obesity, Morbid

Summary: rationale: weight loss therapies should aim to reduce fat mass while preserving both muscle mass and muscle strength. consequently, there is a need for validated methods to measure muscle mass and strength. current methods are either expensive and require trained technicians, or have not been validated in populations with class ii/iii obesity (bmi \> 35 kg/m2). in our previous studies (must-mop and muscle study), we have validated the use of ultrasound (us) for the measurement of lean mass (a proxy for muscle mass) in a population with obesity. these studies showed that the use of us for the measurement of lean mass was feasible, reliable and valid. the aim of the current study is to validate the use of us for the measurement of lean mass after weight loss in a population of bariatric surgery patients. objective: primary objective: to assess the validity of us to measure lean mass after weight loss in a population of bariatric surgery patients. secondary objectives: * to assess de differences in lean mass between dxa and us in this study compared to the muscle-study. * to assess how the lean mass has changed after bariatric surgery and the effects of lean mass on total weight loss and resolution of comorbidities * to assess whether the change in lean mass has an effect on serum levels of markers for muscle mass. study design: this study is an observational follow-up study of the muscle study and will take place in the centre obesity northern-netherlands (con) at the medical centre leeuwarden (mcl). study population: the population will consists of participants, who have participated in the muscle study and have received bariatric surgery at the con / mcl. main study parameters/endpoints: the main parameters of this study are: lean mass measured by dxa and us. the main endpoint of this study is the validity of the us measurement of lean mass compared to dxa. nature and extent of the burden and risks associated with participation, benefit and group relatedness: there are no direct benefits for the participants. however, the results of this study can help to further validate the ultrasound as a cheaper and more accessible method to measure muscle mass. this can potentially be used in standard clinical care to assess muscle mass of patients during weight loss. • the additional time investment: during first year follow-up appointment approximately 30 minutes. the risks of most test are minor, even the small amount of radiation exposure, which means the risks and burden of this study outweigh the potentially obtainable knowledge.


Eligibility criteria:
inclusion criteria: * participation muscle study * ±1 year after bariatric surgery exclusion criteria: * inability to communicate in either dutch or english * weight over 204 kilograms (due to limitations of the dxa) * pregnancy * pacemaker

Keywords: muscle mass sonography
study of mycamine® in infants and toddlers with fungal infections to evaluate safety and blood levels of the drug

Conditions: Invasive Candidiasis; Esophageal Candidiasis; Oropharyngeal Candidiasis; Candidemia

Summary: infants and toddlers with fungal infections will receive 10 to 14 days of treatment with an antifungal drug. safety and drug blood levels will be assessed

this is a prospective, multicenter, open-label, repeat-dose study. subjects will receive treatment with intravenous micafungin for 10 to 14 days (per investigator clinical judgment) at a daily dose of 4.5 mg/kg (determined by the subject's weight at baseline). serial blood samples for assessment of pharmacokinetics will be collected.

Eligibility criteria:
inclusion criteria: 1. subject is ≥4 months to \< 24 months 2. subject has suspected, proven or probable candidiasis, candidemia or other invasive candidiasis 3. subject has sufficient venous access to permit administration of study medication, collection of pharmacokinetic samples, and monitoring of laboratory safety variables exclusion criteria: 1. subject has evidence of significant liver disease, as defined by aspartate transaminase (ast), alanine transaminase (alt), bilirubin or alkaline phosphatase \> 5 times the upper limit of normal (uln) 2. subject has a concomitant medical condition that in the opinion of the investigator and/or medical monitor precludes enrollment into the study 3. subject has a history of anaphylaxis, hypersensitivity, or any serious reaction to the echinocandin class of antifungals 4. subject has received treatment with an echinocandin within one week prior to first dosing 5. subject status is unstable and subject is unlikely to complete all study required procedures

Keywords: antifungal echinocandin candidiasis micafungin
the university of hong kong neurocognitive disorder cohort

Conditions: Neurocognitive Disorder; Mild Cognitive Impairment; Alzheimer Dementia; Vascular Dementia; Age-related Cognitive Decline

Summary: the hku neurocognitive disorder (ncd) cohort is a hospital-based, prospective, observational study of older hk chinese adults with cognitive impairment, with a special focus on studying patients with subjective cognitive decline and mild cognitive impairment.

the hku neurocognitive disorder (ncd) cohort is a hospital-based, prospective, observational study of older hk chinese adults with cognitive impairment, with a special focus on studying patients with subjective cognitive decline and mild cognitive impairment, and in particular the biomarkers that predict cognitive and functional decline. comprehensive profiling of each subject is performed through a multi-domain assessment protocol including detailed demographics, lifestyle factors, neuropsychological battery, mood, mri, genetics, blood biomarkers, and other patient-centred parameters including level of disability, quality of life and societal engagement. ongoing annual follow up captures the essential clinical events and changes in neurocognitive function (conversion to mci or dementia), mood, level of disability and quality of life; as well as repeat blood tests. the hku ncd cohort is the first-ever asian dementia cohort to be formally included into the dementia platforms uk, achieving an international collaborative status with other uk-based cohorts. the study neuropsychological battery is aligned with the nacc uds3 battery.

Eligibility criteria:
inclusion criteria: * older adults with or without neurocognitive disoder. hku ncd cohort focuses primarily on people with subjective cognitive decline (scd) and mild cognitive impairment (mci). exclusion criteria: * severe parkinson's disease, major depressive disorder or severe psychiatric conditions, significant communication difficulties (e.g. aphasia, deafness), terminal cancer or likely end-of-life in the next 12 months.

Keywords: subjective cognitive decline mild cognitive impairment dementia cerebral aging
comparison of 0.1 and 0.05mg intrathecal morphine for post-cesarean analgesia.

Conditions: Cesarean Section

Summary: the purpose of this study is to determine the ideal dose of spinal morphine for use in cesarean section. spinal anesthesia (single injection in the lower back to numb patients from the waist down) is commonly used in cesarean section to provide numbness and pain relief during the surgery, and adding morphine to the spinal anesthetic provides long lasting pain relief for up to 24 hours after surgery. the ideal dose of spinal morphine, when given with other types of pain medications such as nonsteroidal anti-inflammatories and acetaminophen, has not been determined. in addition, spinal morphine can have side effects such as nausea and itching, so using a lower dose of morphine may decrease these side effects while providing the same amount of postoperative pain relief. study participants will be divided into two groups. group 1 will receive the standard dose of spinal morphine (0.1mg) while group 2 will receive a lower dose of spinal morphine (0.05mg). both groups will receive the standard dose of spinal bupivacaine (numbing medication) and spinal fentanyl (short acting pain medication). the additional pain medications (iv toradol and oral acetaminophen) will be given to both groups after surgery. pain control and morphine side effects will be compared between the two groups in order to determine the best dose of spinal morphine for cesarean section.


Eligibility criteria:
inclusion criteria: * any parturient 18 years of age or older * undergoing elective cesarean delivery under spinal anesthesia * able to consent to the study and participate in the follow-up. exclusion criteria: * any known allergy to morphine * general anesthesia * urgent or emergent cases * any bleeding diathesis or other coagulopathy * known g6pd deficiency * any known liver disease * known alcohol abuse or dependence * hellp syndrome * thrombocytopenia or known platelet dysfunction * history or active gastrointestinal bleeding * acute kidney injury or chronic renal insufficiency * contraindication/refusal to spinal anesthestic * chronic pain * chronic narcotic use * illicit drug use * allergy to any study related medications
a double-blind, double-dummy, parallel, active-controlled, randomized trial to evaluate efficacy & safety in anemia subjects

Conditions: Iron Deficiency Anemia

Summary: to evaluate the efficacy and safety of 12 weeks treatment with ferrous (ii) glycine sulphate complex in comparison to polyferose capsules in chinese subjects with manifest iron deficiency anemia.


Eligibility criteria:
inclusion criteria: * an iron deficiency anemia patient with serum ferritin \ 60 and \< 120 g/l in males, \< 110 g/l in females exclusion criteria: * with any mal-absorption syndrome * with a history of thalassemia or sickle cell anemia * with untreated concurrent vitamin b12 or folate deficiency at baseline

Keywords: ferrous (ii) glycine sulphate complex polyferose ferro sanol duodenal niferex iron deficiency anemia
comparison of peng block and sificb in hip fracture surgeries

Conditions: Hip Fracture; Pericapsular Nerve Group Block (PENG Block); Suprainguinal Fasya Iliaca Block

Summary: the aim of this study is to compare the effectiveness of the peng block and sifib in facilitating the positioning for neuroaxial anesthesia and their impact on the quality of postoperative analgesia.

hip fractures are a significant health problem that leads to severe morbidity and mortality in elderly individuals. neuroaxial anesthesia is often preferred in the surgical treatment of these patients due to its ability to maintain hemodynamic stability and manage postoperative analgesia. however, the severe pain accompanying these fractures makes it difficult to achieve an appropriate position for neuroaxial anesthesia, which complicates both patient comfort and the work of the anesthesia provider. in recent years, peripheral nerve blocks have emerged as an effective method to overcome this challenge. the pericapsular nerve group (peng) block and supra-inguinal fascia iliaca compartment block (sifib) are commonly used techniques for the management of pain related to hip fractures. while studies comparing the analgesic efficacy of these two blocks exist in the literature, data regarding their specific effects on neuroaxial anesthesia positioning are limited. in this study, patients scheduled for surgery due to hip fractures will receive either a pericapsular nerve group (peng) block or a supra-inguinal fascia iliaca compartment block (sifib). both block procedures will be performed under ultrasound guidance and sterile conditions, following standard protocols. after the block procedure, the time taken for patients to transition into the neuroaxial anesthesia position (primary outcome) will be measured, and the level of pain experienced during positioning will be assessed using the visual analog scale (vas). in the postoperative period, vas scores and additional analgesic requirements (secondary outcomes) will be recorded for 24 hours. demographic data (age, gender, body mass index) and comorbidities will also be collected and used for intergroup comparisons. throughout the study, patient privacy will be respected, and the collected data will be analyzed anonymously. the study will be conducted in accordance with the declaration of helsinki, and informed consent will be obtained from all participants.

Eligibility criteria:
inclusion criteria: * hip fractures * 40-80 years exclusion criteria: * contraindicated to spinal anesthesia * allergy to local anesthetics * severe peripheral neuropathy * mental disorders

Keywords: hip fracture pericapsular nerve group block suprainguinal fasya iliaca block patient positioning
a trial of cmna combined with definitive concurrent chemoradiotherapy for locally advanced escc

Conditions: Esophageal Neoplasms

Summary: this is a perspective, multicenter,randomized controlled trial to evaluate the efficacy and safety of treatment with cmna combined with concurrent chemoradiotherapy in patients with locally advanced squamous cell esophageal carcinoma . analyses of primary objective (orr) will be done as defined in the protocol.

the primary end point of this study is objective response rate.the secondary end point is os, pfs and the safty of drug. the primary hypothesis is the cmna will improve orr and thus improve os, pfs. assuming bilateral a=0.05, statistical power of 80%.the total sample size is 104 cases.

Eligibility criteria:
inclusion criteria: 1. signed written informed consent prior to study entry 2. patients with escc in upper and middle thoracic segment（stage ii-iii）confirmed by imaging and pathology or cytology, which is unsuitable or refuse surgery; 3. capable for chemo-radiotherapy; 4. the existence of measurable lesions; 5. ecog ps of 0 or 1 6. possible semi-liquid diet; 7. expected lifetime≥3 months 8. normal bone marrow reserve: anccount ≥1500/mm3;platelet count ≥100,000/ mm3,hemoglobin≥9g/dl 9. normal hepatic funcion:bilirubin level ≤1.5×uln;ast/alt≤1.5×uln 10. normal renal function: serum creatinine≤1.5mg/dl and calculated creatinine clearance ≥60ml/min 11. normal cardiac function 12. subjects tumor tissue available for the relevant biomarker detection exclusion criteria: 1. female subject who is during pregnancy or lactation, and the subject who have fertility don't take effective contraception during study 2. any mental illness or nervous system lesions or can't tell treatment response clearly (such as cerebrovascular accident sequelae) 3. any serious uncontrolled disease and infection, such as severe heart, liver, kidney diseases or diabetes, can't complete the treatment plan 4. patients who have other malignant lesions, except curable skin cancer (non-melanoma skin cancer),carcinoma in situ of cervix or serve disease cured for 5 years 5. primary lesions were multifocal 6. patients who have obvious esophageal ulcers or have above moderate pains in chest-back or have symptoms of esophageal perforation 7. received anti-cancer treatment of esophageal cancer before the group, including surgery, radiotherapy, chemotherapy (induction of chemotherapy before the group is greater than or equal to two cycles). 8. not esophageal squamous carcinoma confirmed by pathology or cytology 9. history of active hepatitis 10. unable to comprehend the study requirement or who are not likely to comply with the study requirements 11. significant disease which, in the investigator's opinion, would exclude the patient from the study
cultural differences in treatment preferences and perceptions of acne

Conditions: Acne Vulgaris

Summary: this study will use a survey to examine relationships between culture, race, and ethnicity with treatment preferences and perceptions for acne vulgaris.

the purpose of this study is to determine how explanatory models, perceptions, and treatment preferences of acne vulgaris vary across different cultures and racial and ethnic backgrounds. this study will also use willingness to pay to investigate differences in treatment valuation. clarifying these differences will better inform patient counseling and treatment adherence by improving the quality of shared decision making.

Eligibility criteria:
inclusion criteria: * subjects must have acne vulgaris, be at least 18 years of age, and must be able to complete a survey published in english. exclusion criteria: -
sequential car-t cells targeting cd33/cd123 in patients with acute myelocytic leukemia aml

Conditions: AML; Acute Myeloid Leukemia; AML, Adult Recurrent; AML, Adult

Summary: this is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor t cell immunotherapy (car-t) targeting cd33 or cd123 or both sequentially in the treatment of acute myelocytic leukemia.

chimeric antigen receptor (car)-modified t cells targeted against cd19 have demonstrated unprecedented successes in treating patients with hematopoietic and lymphoid malignancies. besides cd19, many other molecules such as cd22, cd30,bcma,cd123, etc. may have the potential to develop the corresponding car-t cells to treat patients whose tumors express those markers. in this study, investigators will evaluate the safety and efficacy of car-t targeting cd33/cd123 in patients with acute myelocytic leukemia. the primary goal is safety assessment including cytokine storm response and any other adverse effects. in addition, disease status after treatment will also be evaluated. the purpose of this clinical trial is to assess the feasibility, safety, and efficacy of multiple car t-cell therapy which combines car t cells against aml cells with car t cells targeting cd123 or cd33 in patients with relapsed and refractory aml. the study also aims to learn more about the function of car t cells and their persistence in aml patients.

Eligibility criteria:
inclusion criteria: * subjects with acute myeloid leukemia who voluntarily signed informed consent and met the following criteria: * age older than 6 months. * confirmed expression of cll-1, cd123 and/or cd33 in blast aml by immuno-histochemical staining or flow cytometry. * karnofsky performance status (kps) score is higher than 80 and life expectancy \> 3 months. * adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: cardiac ejection fraction ≥ 50%, oxygen saturation ≥ 90%, creatinine ≤ 2.5 × upper limit of normal, aspartate aminotransferase (ast) and alanine aminotransferase (alt) ≤ 3 × upper limit of normal, total bilirubin ≤ 2.0mg/dl. * hgb≥80g/l. * no cell separation contraindications. * abilities to understand and the willingness to provide written informed consent. exclusion criteria: * severe illness or medical condition, which would not permit the patient to be managed according to the protocol, including active uncontrolled infection. * active bacterial, fungal or viral infection not controlled by adequate treatment. * known hiv, hepatitis b virus (hbv) or hepatitis c virus (hcv) infection. * pregnant or nursing women may not participate. * use of glucocorticoid for systemic therapy within one week prior to entering the trial. * patients, in the opinion of investigators, may not be able to comply with the study.

Keywords: aml cd33 cd123 car-t